Variable | SOC, n = 22 | CTMR, n = 19 | Total No. Patients, n = 41 | |||
---|---|---|---|---|---|---|
Mean (SD) | N (% of total) | Mean (SD) | N (% of total) | Mean (SD) | N (% of total) | |
Age at the time of the study, yrs | 18.6 (2.6) | 18.7 (2.5) | 18.6 (2.5) | |||
Weight, kg | 75 (18.2) | 71 (18.7) | 73 (18.4) | |||
Medications | ||||||
HCQ, mg/day | 327 (93) | 324 (75) | 326 (84) | |||
HCQ, mg/kg/day | 4.6 (1.6) | 4.8 (1.2) | 4.7 (1.4) | |||
HCQ dose frequency | ||||||
Every other day | 1 (4) | 1 (5) | 2 (5) | |||
1 time a day | 18 (82) | 15 (79) | 23 (80) | |||
2 times a day | 3 (14) | 3 (16) | 6 (15) | |||
Prednisone, mg/day | 14 (17) | 15 (19) | 14 (17.5) | |||
Pulse methylprednisolone | — | 3 (16) | 3 (7) | |||
Nonsteroidal antiinflammatory drugs | 8 (36) | 10 (53) | 18 (44) | |||
Immunosuppressive medications* | 15 (68) | 14 (74) | 29 (71) | |||
Antihypertensive medications | 12 (55) | 8 (42) | 20 (49) | |||
Disease activity indices | ||||||
Disease activity (SLEDAI) | 3.7 (4.0) | 7.9 (7.1) | 5.5 (5.9) | |||
Disease damage (SDI) | 0.8 (1.6) | 0.7 (1.7) | 0.8 (1.6) | |||
Physician global assessment of disease activity** | 1.9 (1.6) | 2.8 (2.3) | 2.3 (2.0) | |||
Patient well-being† | 7.6 (2.0) | 7.2 (1.9) | 7.4 (1.9) | |||
Medication adherence | ||||||
MASRI | 80 (21) | 83 (19) | 81 (20) | |||
Pharmacy refill data | 52 (32) | 64 (45) | 57 (33) | |||
No. patients with adherence > 80% | 6 (27) | 7 (37) | 13 (32) | |||
HCQ levels†† (p < 0.03) | 0.46 (0.55) | 0.64 (0.45) | 0.54 (0.51) |
↵* E.g., mycophenolate mofetil, azathioprine. SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; 0 = inactive disease. SDI: Systemic Lupus International Collaboration Clinics Damage Index; 0 = no damage.
↵** Visual analog scale 0 to 10; 0 = inactive disease; 10 = very active disease.
↵† Visual analog scale 0 to 10; 0 = very poor; 10 = very well. MASRI: Medication Adherence Self-Report Inventory (0 to 100); 0 = no medication taken; 100 = all doses taken as prescribed.
↵†† Concentration measured in blood.